Longevity Medicine Ethics Standards
The American Society, Board and Council of Longevity Medicine have created the first Longevity Medicine Ethics Standards as a foundational pillar of the formal development of Longevity Medicine as a globally recognized medical specialty.
Preamble
Longevity medicine represents a rapidly evolving domain integrating preventive care, regenerative biology, and experimental therapeutics. Given the gap between mechanistic promise and clinical validation, physicians must adhere to rigorous ethical standards to ensure patient safety, scientific integrity, and public trust.
Core Ethical Principles
1. Evidence-Based Practice: Prioritize interventions supported by clinical evidence and clearly distinguish between established, off-label, and investigational therapies.
2. Transparency of Evidence: Disclose limitations, including reliance on preclinical data, biomarkers, and lack of validated lifespan or healthspan outcomes.
3. Enhanced Informed Consent: Clearly communicate experimental status, risks, uncertainties, and absence of long-term outcome data.
4. Avoidance of Misleading Claims: Do not promote unproven claims such as age reversal, lifespan extension, or systemic rejuvenation.
5. Regulatory Compliance: Adhere to federal, state and local regulations, including biologic classifications, approved indications, and truthful marketing.
6. Patient Safety First: Minimize the potential for harm by avoiding unnecessary or unproven interventions and monitoring for adverse effects.
7. Product Quality and Standardization: Use therapies with known composition, quality control, and reproducible manufacturing standards.
8. Objective Outcome Measurement: Focus on functional, clinically meaningful endpoints rather than surrogate biomarkers alone.
9. Conflict of Interest Disclosure: Avoid financial bias and ensure recommendations are patient-centered and transparent.
10. Responsible Innovation: Support ethical research, data transparency, and rigorous clinical trials before widespread adoption.
